» Articles » PMID: 38459166

Targeting the Innate Immune System in Pediatric and Adult AML

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2024 Mar 8
PMID 38459166
Authors
Affiliations
Soon will be listed here.
Abstract

While the introduction of T cell-based immunotherapies has improved outcomes in many cancer types, the development of immunotherapies for both adult and pediatric AML has been relatively slow and limited. In addition to the need to identify suitable target antigens, a better understanding of the immunosuppressive tumor microenvironment is necessary for the design of novel immunotherapy approaches. To date, most immune characterization studies in AML have focused on T cells, while innate immune lineages such as monocytes, granulocytes and natural killer (NK) cells, received less attention. In solid cancers, studies have shown that innate immune cells, such as macrophages, myeloid-derived suppressor cells and neutrophils are highly plastic and may differentiate into immunosuppressive cells depending on signals received in their microenvironment, while NK cells appear to be functionally impaired. Hence, an in-depth characterization of the innate immune compartment in the TME is urgently needed to guide the development of immunotherapeutic interventions for AML. In this review, we summarize the current knowledge on the innate immune compartment in AML, and we discuss how targeting its components may enhance T cell-based- and other immunotherapeutic approaches.

Citing Articles

Selected Elements of the Tumor Microenvironment (MMP-2, MMP-7, TIMP-2, CXCL-9, CXCL-10) in the Serum of Pediatric Patients with Acute Lymphoblastic Leukemia.

Kaczorowska A, Miekus-Purwin N, Owczarzak A, Gabrych A, Wojciechowska M, Irga-Jaworska N Cells. 2025; 14(4).

PMID: 39996769 PMC: 11854448. DOI: 10.3390/cells14040297.


The Role of Chronic Inflammation in Pediatric Cancer.

Mella C, Tsarouhas P, Brockwell M, Ball H Cancers (Basel). 2025; 17(1.

PMID: 39796780 PMC: 11719864. DOI: 10.3390/cancers17010154.


Research Hotspots and Trends of NK Cell Immunotherapy for Acute Myeloid Leukemia: A Bibliometric Analysis From 2000 to 2023.

Chen S, Liu J, Xia K, Gao Y, Zeng Y Cancer Control. 2024; 31:10732748241310937.

PMID: 39703189 PMC: 11660279. DOI: 10.1177/10732748241310937.


MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia.

Kegyes D, Thiagarajan P, Ghiaur G Cancers (Basel). 2024; 16(18).

PMID: 39335179 PMC: 11430625. DOI: 10.3390/cancers16183208.


The interaction of innate immune and adaptive immune system.

Wang R, Lan C, Benlagha K, Camara N, Miller H, Kubo M MedComm (2020). 2024; 5(10):e714.

PMID: 39286776 PMC: 11401974. DOI: 10.1002/mco2.714.


References
1.
Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E . Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021; 11(2):41. PMC: 7900255. DOI: 10.1038/s41408-021-00425-3. View

2.
Zwaan C, Kolb E, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R . Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2015; 33(27):2949-62. PMC: 4567700. DOI: 10.1200/JCO.2015.62.8289. View

3.
Isidori A, Cerchione C, Daver N, DiNardo C, Garcia-Manero G, Konopleva M . Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Front Oncol. 2021; 11:656218. PMC: 8143531. DOI: 10.3389/fonc.2021.656218. View

4.
Karlsson L, Cheuk D, De Moerloose B, Hasle H, Jahnukainen K, Juul-Dam K . Characteristics and outcome of primary resistant disease in paediatric acute myeloid leukaemia. Br J Haematol. 2023; 201(4):757-765. DOI: 10.1111/bjh.18685. View

5.
Orti G, Barba P, Fox L, Salamero O, Bosch F, Valcarcel D . Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. Exp Hematol. 2016; 48:1-11. DOI: 10.1016/j.exphem.2016.12.004. View